Related references
Note: Only part of the references are listed.Morbidity-free survival and hemoglobin level in non-transfusion-dependent β-thalassemia: a 10-year cohort study
Khaled M. Musallam et al.
ANNALS OF HEMATOLOGY (2022)
Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years
Khaled M. Musallam et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later
Khaled M. Musallam et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
Naja Nyffenegger et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Gene therapy using haematopoietic stem and progenitor cells
Giuliana Ferrari et al.
NATURE REVIEWS GENETICS (2021)
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
H. Frangoul et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
Sherif M. Badawy et al.
BLOOD ADVANCES (2021)
Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia
Khaled M. Musallam et al.
ANNALS OF HEMATOLOGY (2021)
Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders
Marina Ere Hummel Pimenta Santos et al.
BLOOD CELLS MOLECULES AND DISEASES (2021)
Benserazide racemate and enantiomers induce fetal globin gene expression in vivo: Studies to guide clinical development for beta thalassemia and sickle cell disease
Betty S. Pace et al.
BLOOD CELLS MOLECULES AND DISEASES (2021)
β-Thalassemias
Ali T. Taher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells
Giulia Pavani et al.
BLOOD ADVANCES (2021)
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients
Dinesh Bhurani et al.
ANNALS OF HEMATOLOGY (2021)
Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia-a pilot study from a tertiary care Centre of India
Manisha Jain et al.
BLOOD CELLS MOLECULES AND DISEASES (2021)
Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent β-thalassaemia
Ali T. Taher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia
Jim Vadolas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia
Khaled M. Musallam et al.
HAEMATOLOGICA (2021)
Inclusion of a short hairpin RNA targeting BCL11A into a beta-globin expressing vector allows concurrent synthesis of curative adult and fetal hemoglobin
Silvia Pires Lourenco et al.
HAEMATOLOGICA (2021)
Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm
Donatella Baronciani et al.
HEMASPHERE (2021)
A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease
James G. McArthur et al.
HAEMATOLOGICA (2020)
Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers
Frank Richard et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Safety and effectiveness of thalidomide and hydroxyurea combination in β-thalassaemia intermedia and major: a retrospective pilot study
Sandip Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major
Carla Casu et al.
HAEMATOLOGICA (2020)
Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience
Arijit Nag et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2020)
Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
Vania Manolova et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Emerging therapies in β-thalassemia: toward a new era in management
Rayan Bou-Fakhredin et al.
EXPERT OPINION ON EMERGING DRUGS (2020)
Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability
Pedro A. Martinez et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Thalidomide for Patients with β-Thalassemia: A Multicenter Experience
Kun Yang et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2020)
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
M. D. Cappellini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Gene therapies for transfusion dependent beta-thalassemia: Current status and critical criteria for success
Sandeep Soni
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
Irene Motta et al.
DRUGS (2020)
Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity
Carla Casu et al.
BLOOD (2020)
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease
Matthew M. Hsieh et al.
BLOOD ADVANCES (2020)
The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients
Kun Yang et al.
BLOOD CELLS MOLECULES AND DISEASES (2020)
Changing patterns in the epidemiology of β-thalassemia
Antonis Kattamis et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial
Ali T. Taher et al.
BLOOD (2020)
Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial
Olivier Hermine et al.
BLOOD (2020)
Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial
Maria Domenica Cappellini et al.
BLOOD (2020)
National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality
Ersi Voskaridou et al.
ANNALS OF HEMATOLOGY (2019)
Gene therapy of hemoglobinopathies: progress and future challenges
Yasuhiro Ikawa et al.
HUMAN MOLECULAR GENETICS (2019)
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Elisa Magrin et al.
BLOOD (2019)
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
Rachael F. Grace et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia
Angela R. Smith et al.
BLOOD (2019)
Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©)
Ali Taher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©)
Ali Taher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia
Stefano Rivella
BLOOD (2019)
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia
Antonio Piga et al.
BLOOD (2019)
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study
Maria Domenica Cappellini et al.
HAEMATOLOGICA (2019)
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β-thalassemia
Sarah Marktel et al.
NATURE MEDICINE (2019)
Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers
Hua Yang et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia
Alessandro Matte et al.
JCI INSIGHT (2019)
Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of beta-thalassemia intermedia and major
Carla Casu et al.
HAEMATOLOGICA (2018)
Thalidomide has a significant effect in patients with thalassemia intermedia
YunShuan Li et al.
HEMATOLOGY (2018)
Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of beta-thalassemia intermedia and major
Carla Casu et al.
HAEMATOLOGICA (2018)
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia
Quan Ren et al.
ANNALS OF HEMATOLOGY (2018)
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Chiara Antoniani et al.
BLOOD (2018)
Gene Therapy and Genome Editing
Farid Boulad et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
A. A. Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
How I manage medical complications of β-thalassemia in adults
Ali T. Taher et al.
BLOOD (2018)
Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with beta-Thalassemia Major
Nikoletta Psatha et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study
Ali T. Taher et al.
BLOOD (2018)
Thalidomide induces haematologic responses in patients with -thalassaemia
Jiangming Chen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia
Carla Casu et al.
HAEMATOLOGICA (2016)
Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia
Carla Casu et al.
HAEMATOLOGICA (2016)
Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice
Antonella Nai et al.
BLOOD (2016)
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Carla Casu et al.
BLOOD (2016)
Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms
Yan Dai et al.
BLOOD CELLS MOLECULES AND DISEASES (2016)
Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases
Carmen F. Bjurstrom et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia
Paul J. Schmidt et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice
Michael S. Boosalis et al.
PLOS ONE (2015)
Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia
Rajasekhar N. V. S. Suragani et al.
BLOOD (2014)
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation
Farid Boulad et al.
BLOOD (2014)
Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Olivier Negre et al.
CURRENT GENE THERAPY (2014)
Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study
Khaled M. Musallam et al.
HAEMATOLOGICA (2014)
Identification of erythroferrone as an erythroid regulator of iron metabolism
Leon Kautz et al.
NATURE GENETICS (2014)
Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
Rajasekhar N. V. S. Suragani et al.
NATURE MEDICINE (2014)
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/- mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia
Paul J. Schmidt et al.
BLOOD (2013)
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
Khaled M. Musallam et al.
BLOOD (2013)
Non-transfusion-dependent thalassemias
Khaled M. Musallam et al.
HAEMATOLOGICA (2013)
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice
Shuling Guo et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
Ali T. Taher et al.
BLOOD (2012)
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia
Antonella Nai et al.
BLOOD (2012)
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia
Khaled M. Musallam et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload
Gloria C. Preza et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
Ali T. Taher et al.
BLOOD (2010)
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Sara Gardenghi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Marina Cavazzana-Calvo et al.
NATURE (2010)
Amelioration of Sardinian β0 thalassemia by genetic modifiers
Renzo Galanello et al.
BLOOD (2009)
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia
Ilaria V. Libani et al.
BLOOD (2008)
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and Amelioration of the phenotype of β-thalassemia
Manuela Uda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Vijay G. Sankaran et al.
SCIENCE (2008)
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance
Bernadette Modell et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2008)
A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15
Stephan Menzel et al.
NATURE GENETICS (2007)
Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity
S Aizawa et al.
EXPERIMENTAL HEMATOLOGY (2005)
Survival in β-thalassaemia major in the UK:: data from the UK thalassaemia register
B Modell et al.
LANCET (2000)
Share Paper
